As predicted, after post-hoc testing, Parkinson's patients who have the DAT1 10/10 genotype demonstrated a decrease on average in bold signal from neutral to rewarded trials, whereas those with other genotypes demonstrated a normal increase in activity [F(1) = 1.678, p = 0.22, partial η2 = 0.123). This evidence concerns the gene SLC6A3 and Parkinson disease.